Journal
JOURNAL OF NUCLEAR CARDIOLOGY
Volume 24, Issue 1, Pages 256-264Publisher
SPRINGER
DOI: 10.1007/s12350-015-0309-y
Keywords
Cardiac sympathetic activity; I-123-mIBG; left ventricular function; anthracycline
Ask authors/readers for more resources
Purpose. The goal of this study was to evaluate late cardiotoxic effects of anthracyclines (ATC) by evaluating cardiac sympathetic activity in a cohort of asymptomatic patients previously treated with ATC for childhood cancers. Methods. We studied 89 asymptomatic patients previously treated with ATC with a normal echocardiogram (49 men and 40 women) and a control group of 40 healthy individuals (26 men and 14 women). Both groups underwent planar myocardial I-123-meta-iodobenzylguanidine scintigraphy (I-123-mIBG). From these images, the early and late heart-to-mediastinum (H/M) ratio and washout rate (WR) were assessed. Results. The mean survival at the time of the I-123-mIBG scintigraphy was 5.3 +/- 3.4 years. Patients treated with ATC had a lower but clinical normal left ventricular ejection fraction (LVEF) compared to controls (60.44 +/- 6.5 vs 64.1 +/- 6.0%, P < 0.01). Both the late H/M ratio and WR were not able to discriminate ATC treated patients from controls. The cumulative ATC dose was the only independent predictor of the LVEF, explaining approximately 12% of the variation in LVEF (P = 0.01). Conclusions. Although the pathophysiology behind ATC cardiotoxicity is most likely multifactorial, myocardial sympathetic activity is not associated with a reduction in LVEF 5-years after completion of chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available